drugset
Drugs / Tumor associated antigen lymphocytes
last change Jan 2015 re-read 3 minutes ago

Tumor associated antigen lymphocytes

also known as TAA-T
Developed for
acute myeloid leukemia
Investigated by
Catherine Bollard · Children's National Research Institute · Johns Hopkins University

Trials 1

today NCT02203903 · Ph 1
2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02203903 Jan 2015 → Nov 2026 expected acute myeloid leukemia Catherine Bollard Recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Tumor associated antigen lymphocytes “Tumor associated antigen lymphocytes (TAA-T)” NCT02203903 ↗
Known as TAA-T ClinicalTrials.gov intervention name — accepted as the source's own label NCT02203903 ↗
Action Deplete “inducing selective expansion of T cells targeted to kill tumor cells.” NCT02203903 ↗